` SBFM (Sunshine Biopharma Inc) vs S&P 500 Comparison - Alpha Spread

SBFM
vs
S&P 500

Over the past 12 months, SBFM has underperformed S&P 500, delivering a return of -77% compared to the S&P 500's 9% growth.

Stocks Performance
SBFM vs S&P 500

Loading
SBFM
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
SBFM vs S&P 500

Loading
SBFM
S&P 500
Difference
www.alphaspread.com

Performance By Year
SBFM vs S&P 500

Loading
SBFM
S&P 500
Add Stock

Competitors Performance
Sunshine Biopharma Inc vs Peers

S&P 500
SBFM
ABBV
AMGN
GILD
VRTX
Add Stock

Sunshine Biopharma Inc
Glance View

Market Cap
6.7m USD
Industry
Biotechnology

Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.

SBFM Intrinsic Value
Not Available
Back to Top